Form 4: OrbiMed Advisors Sells 83,695 Shares of ARS Pharmaceuticals

OrbiMed Advisors LLC, a significant shareholder in ARS Pharmaceuticals, Inc. (SPRY), sold 83,695 shares of common stock on August 26, 2024, at an average price of $13 per share.

Summary

• On August 26, 2024, OrbiMed Advisors LLC sold 83,695 shares of ARS Pharmaceuticals, Inc. (SPRY) common stock.
• The sale price ranged from $12.59 to $13.35 per share, with a weighted average of $13.
• The shares are indirectly held through various OrbiMed-related entities, including OrbiMed Partners Master Fund Limited, OPI VI IP HoldCo LLC, and OrbiMed Private Investments VI, LP.
• OrbiMed Advisors, OrbiMed Capital GP VI LLC, and OrbiMed Capital LLC disclaim beneficial ownership of the securities, except to the extent of their pecuniary interest.
• Peter Thompson, a member of OrbiMed Advisors, serves on the Issuer's board of directors.

Sentiment

Score: 5

Explanation: Neutral sentiment. The document simply reports a transaction. The sale of shares by a major holder could be interpreted negatively, but it's a routine disclosure.

Negatives

• OrbiMed Advisors selling a portion of its holdings could be perceived negatively by the market.

Risks

• Continued sales by major shareholders like OrbiMed could put downward pressure on the stock price.

Management Comments

• OrbiMed Advisors, GP VI, and OrbiMed Capital disclaim beneficial ownership of the securities reported, except to the extent of their pecuniary interest.

Industry Context

Form 4 filings are standard disclosures required by the SEC when insiders or major shareholders of a publicly traded company buy or sell the company's stock. This filing indicates a change in OrbiMed's holdings in ARS Pharmaceuticals.

Comparison to Industry Standards

• Form 4 filings are a common occurrence for publicly traded companies and their major shareholders.
• The sale of shares by OrbiMed is not unusual, as investment firms often adjust their holdings based on their investment strategies and market conditions.
• Comparable transactions would be other Form 4 filings by major shareholders in similar pharmaceutical companies.

Stakeholder Impact

• The sale of shares by OrbiMed could potentially impact shareholder sentiment and the stock price of ARS Pharmaceuticals.

Key Dates